{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:31:43Z","timestamp":1783139503297,"version":"3.54.6"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"7631","license":[{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,11,30]],"date-time":"2016-11-30T00:00:00Z","timestamp":1480464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2016,12,1]]},"DOI":"10.1038\/nature19838","type":"journal-article","created":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T17:04:35Z","timestamp":1480439075000},"page":"E1-E2","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Consistency in large pharmacogenomic studies"],"prefix":"10.1038","volume":"540","author":[{"given":"Paul","family":"Geeleher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Gamazon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathal","family":"Seoighe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy J.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Stephanie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,30]]},"reference":[{"key":"BFnature19838_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/nature12831","volume":"504","author":"B Haibe-Kains","year":"2013","unstructured":"Haibe-Kains, B. et al. Inconsistency in large pharmacogenomic studies. Nature 504, 389\u2013393 (2013)","journal-title":"Nature"},{"key":"BFnature19838_CR2","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012)","journal-title":"Nature"},{"key":"BFnature19838_CR3","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nature11005","volume":"483","author":"MJ Garnett","year":"2012","unstructured":"Garnett, M. J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570\u2013575 (2012)","journal-title":"Nature"},{"key":"BFnature19838_CR4","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","volume":"66","author":"GE Konecny","year":"2006","unstructured":"Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630\u20131639 (2006)","journal-title":"Cancer Res."},{"key":"BFnature19838_CR5","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/jnci\/91.22.1940","volume":"91","author":"LR Kelland","year":"1999","unstructured":"Kelland, L. R., Sharp, S. Y., Rogers, P. M., Myers, T. G. & Workman, P. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. 91, 1940\u20131949 (1999)","journal-title":"J. Natl. Cancer Inst."},{"key":"BFnature19838_CR6","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nature04304","volume":"439","author":"DB Solit","year":"2006","unstructured":"Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358\u2013362 (2006)","journal-title":"Nature"},{"key":"BFnature19838_CR7","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","volume":"70","author":"JR Dry","year":"2010","unstructured":"Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264\u20132273 (2010)","journal-title":"Cancer Res."},{"key":"BFnature19838_CR8","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1073\/pnas.0711741105","volume":"105","author":"J Tsai","year":"2008","unstructured":"Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl Acad. Sci. USA 105, 3041\u20133046 (2008)","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnature19838_CR9","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ijc.22643","volume":"121","author":"CR M\u00fcller","year":"2007","unstructured":"M\u00fcller, C. R. et al. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int. J. Cancer 121, 199\u2013205 (2007)","journal-title":"Int. J. Cancer"},{"key":"BFnature19838_CR10","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2146\/ajhp120261","volume":"70","author":"A Timm","year":"2013","unstructured":"Timm, A. & Kolesar, J. M. Crizotinib for the treatment of non-small-cell lung cancer. Am. J. Health Syst. Pharm. 70, 943\u2013947 (2013)","journal-title":"Am. J. Health Syst. Pharm."},{"key":"BFnature19838_CR11","doi-asserted-by":"publisher","first-page":"R47","DOI":"10.1186\/gb-2014-15-3-r47","volume":"15","author":"P Geeleher","year":"2014","unstructured":"Geeleher, P., Cox, N. J. & Huang, R. S. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 15, R47 (2014)","journal-title":"Genome Biol."},{"key":"BFnature19838_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12885-015-1237-6","volume":"15","author":"S Falgreen","year":"2015","unstructured":"Falgreen, S. et al. Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. BMC Cancer 15, 235 (2015)","journal-title":"BMC Cancer"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/nature19838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature19838","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/nature19838.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T10:19:34Z","timestamp":1718965174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nature19838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,30]]},"references-count":12,"journal-issue":{"issue":"7631","published-print":{"date-parts":[[2016,12,1]]}},"alternative-id":["BFnature19838"],"URL":"https:\/\/doi.org\/10.1038\/nature19838","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,30]]},"assertion":[{"value":"28 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2016","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The received date and affiliation details for author P.G. were corrected in the HTML.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}